← board
NYMXF
distress 8/10 · high distress / dilution risk$0.01+79%today-93% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+68%
Price & events
-81.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+78.6%
1D
-90.0%
1W
-90.9%
1M
-75.1%
3M
-81.1%
6M
-86.9%
1Y
-93.8%
2Y
-99.3%
5Y
-99.6%
All
Overview
- Market Cap
- $945.40K
- Volume
- 3.38K
- 52 Week Range
- $0.01 – $0.15
- Total Shares
- 94.54M
- Float Shares
- 56.10M
- Short %
- 4.65%
- % Held by Insiders
- 45.18%
- % Held by Institutions
- 0.04%
- RVOL
- 0.11x
- Beta
- 13.25
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 94,540,140 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.